Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)-Reference-Cited by-同舟云学术

Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Published:2018-09-19 Issue:1 Volume:2 Page:
ISSN:2509-8020
Container-title:Journal of Patient-Reported Outcomes
language:en
Short-container-title:J Patient Rep Outcomes

Author:

Matza Louis S.,Stewart Katie D.,Paczkowski Rosirene,Coyne Karin S.,Currie Brooke,Boye Kristina S.

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Health Information Management,Health Informatics

Link

http://link.springer.com/article/10.1186/s41687-018-0064-3/fulltext.html

Reference37 articles.

1. Anderson, R. T., Skovlund, S. E., Marrero, D., et al (2004). Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther, 26(4):565–578.

2. Peyrot, M., & Rubin, R. R. (2005). Validity and reliability of an instrument for assessing health-related quality of life and treatment preferences: The insulin delivery system rating questionnaire. Diabetes Care, 28(1), 53–58.

3. Reaney, M., Elash, C. A., & Litcher-Kelly, L. (2016). Patient reported outcomes (PROs) used in recent phase 3 trials for type 2 diabetes: A review of concepts assessed by these PROs and factors to consider when choosing a PRO for future trials. Diabetes Res Clin Pract, 116, 54–67.

4. Szeinbach, S. L., Barnes, J. H., Summers, K. H., & Lenox, S. M. (2004). Development of an instrument to assess expectations of and preference for an insulin injection pen compared with the vial and syringe. Clin Ther, 26(4), 590–597.

5. American Diabetes Association. (2018). 8. Pharmacologic approaches to glycemic treatment: Standards of medical Care in Diabetes—2018. Diabetes Care, 41(Supplement 1), S73–S85.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months;Diabetes, Obesity and Metabolism;2023-09-15

2. Development of a Measure to Assess Attitudes Towards Nasal versus Autoinjector Glucagon Delivery Devices for Treatment of Severe Hypoglycemia;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2022-11

3. A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors;JCO Oncology Practice;2022-09

4. Development and Validation of the Diabetes Pen Experience Measure: A New Patient-Reported Outcome Measure;Journal of Diabetes Science and Technology;2022-03-14

5. Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study;Advances in Therapy;2022-02-04